The firm is a healthcare-focused investment firm based in the United States with a long history of investing in innovative biotechnology and biopharmaceutical companies across both private and public markets. The firm manages dedicated private investment capital focused on emerging life sciences opportunities and typically invests from Seed through Series B financings. Initial investments often average approximately $10M, with substantial capacity for follow-on participation. Investments are primarily structured as equity, although convertible instruments may be utilized for select early-stage opportunities. The firm primarily invests in companies located in North America and Europe.
The firm invests exclusively in therapeutics and biopharmaceutical innovation across a broad range of modalities and disease areas. The firm is modality-agnostic and evaluates opportunities involving small molecules, biologics, antibodies, RNA therapeutics, cell therapies, gene therapies, and other emerging therapeutic platforms. Areas of interest include oncology, immunology, rare diseases, metabolic disorders, and other indications characterized by significant unmet medical need. The firm prioritizes differentiated science, strong biological rationale, and technologies capable of generating meaningful clinical impact. The firm is comfortable investing from the preclinical stage onward and has experience supporting programs through major clinical development milestones.
From a company and management team perspective, the firm seeks strong scientific founders, experienced leadership teams, and companies capable of advancing complex therapeutic programs through value-inflection points. The firm’s investment professionals bring deep scientific, medical, and financial expertise and work closely with portfolio companies as active strategic partners. The firm is open to leading, co-leading, or participating in investment syndicates and frequently assumes active governance roles, including board and observer positions. The firm provides support across financing strategy, clinical development planning, business development, and long-term company building.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment